{
  "nctId": "NCT04042324",
  "briefTitle": "A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients",
  "officialTitle": "A Randomized 3 Period Crossover Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients",
  "protocolDocument": {
    "nctId": "NCT04042324",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-07-12",
    "uploadDate": "2020-06-19T10:07",
    "size": 574691,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04042324/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE1",
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 12,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-09-30",
    "completionDate": "2020-01-16",
    "primaryCompletionDate": "2020-01-16",
    "firstSubmitDate": "2019-07-22",
    "firstPostDate": "2019-08-01"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Adult hemodialysis patients ≥18 years of age.\n2. Signed informed consent to participate in the study.\n3. Stable on hemodialysis prescription for ≥3 months.\n4. Hemoglobin concentration \\>9.5 g/dL.\n5. Serum TSAT ≥20%.\n6. Able to receive continuous heparin infusion as their anticoagulation protocol.\n7. Receiving hemodialysis via AV (arteriovenous) fistula or graft.\n8. Able to receive hemodialysis for 4 hours at each session over the duration of the treatment periods.\n\nExclusion Criteria:\n\n1. Active bleeding disorder (GI, skin, nasal…)\n2. Receiving hemodialysis via catheter.\n3. Receiving heparin free dialysis.\n4. Receiving low molecular weight heparin as sole anti-coagulation for dialysis.\n5. Receiving IV iron within 2 weeks of the first on-study hemodialysis treatment.\n6. Receiving oral anti-coagulants or anti-platelet agents.\n7. Any other condition, that in the opinion of the investigator would not allow completion of the 3 hemodialysis treatments in the study.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-t",
        "timeFrame": "8 hours"
      }
    ],
    "secondary": [
      {
        "measure": "Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-4 Hours",
        "timeFrame": "4 hours"
      },
      {
        "measure": "aPTT (Activated Partial Thromboplastin Time) as Measured by the AUC (Area Under the Curve) 0-4 Hours",
        "timeFrame": "4 hours"
      },
      {
        "measure": "TT (Thrombin Time) as Measured by the AUC (Area Under the Curve) 0-4 Hours",
        "timeFrame": "4 hours"
      },
      {
        "measure": "Iron Profile as Measured by the sFe Cmax (Peak Serum Iron Concentration)",
        "timeFrame": "8 hours"
      },
      {
        "measure": "Iron Profile as Measured by the AUC (Area Under the Curve) 0-t",
        "timeFrame": "8 hours"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 59,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:06.211Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}